Trials / Completed
CompletedNCT01606735
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Ocular Surgery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- ICON Bioscience Inc · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI-10090 | dexamethasone |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2012-05-28
- Last updated
- 2014-09-22
- Results posted
- 2014-09-22
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01606735. Inclusion in this directory is not an endorsement.